Epstein-Barr virus antigen peptide–Human leukocyte antigen class I complex (EBV-HLA-I complex)

The Epstein-Barr virus (EBV) antigen peptide–Human leukocyte antigen (HLA) class I complex is a critical immunological target found on the surface of EBV-infected cells, including various types of EBV-associated tumor cells (Taylor et al., 2015, Nature Reviews Immunology). These complexes consist of short viral peptides derived from EBV latent proteins, such as Latent Membrane Protein 1 (LMP1), LMP2, and EBV Nuclear Antigen 1 (EBNA1), which are processed and presented by the host's HLA class I molecules (Long et al., 2011, Journal of Experimental Medicine). In EBV-positive malignancies like nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder (PTLD), these complexes serve as specific markers that distinguish malignant cells from healthy tissue (Bollard & Heslop, 2016, Blood). Therapeutic strategies targeting these complexes include adoptive T-cell therapies, such as tabelecleucel, and engineered T-cell receptor (TCR) therapies that recognize the specific peptide-HLA combination to induce cytotoxic cell death (Prockop et al., 2020, JCI Insight). Because these targets are highly specific to the viral infection within the tumor, they offer a pathway for precision immunotherapy with potentially lower systemic toxicity compared to traditional chemotherapy (Haque et al., 2007, Lancet Oncology). However, challenges such as HLA restriction and the potential for tumor immune escape through HLA downregulation remain significant hurdles in clinical application (Rancati et al., 2020, Frontiers in Immunology).

Other names

EBV peptide-MHC class I complexEBV-pMHCEpstein-Barr virus peptide-HLA complexEBV-specific peptide-MHC class I complexEBV-HLA class I complex

Recognition of specific viral peptides (e.g., from LMP1, LMP2, or EBNA1) presented by HLA class I molecules by T-cell receptors (TCRs) on cytotoxic T-lymphocytes, leading to the targeted lysis of EBV-positive tumor cells (Bollard & Heslop, 2016, Blood).